OneOme Expands Reach To Five More States

Patent-pending status for its RightMed test.

Minneapolis-based medical startup OneOme LLC continues to raise its profile in the emerging pharmacogenomics industry. On Monday, the company announced that it had earned laboratory certification allowing it to start offering its RightMed test in five additional states: California, Florida, Maryland, Pennsylvania and Rhode Island. OneOme is now able to offer its testing technology in every state except New York, where it is seeking to obtain laboratory certification this year.
The company’s RightMed test deploys software and proprietary algorithms combined with genetic analysis to help determine which medications will work best for individual patients and serves to help minimize adverse drug reactions. The technology is part of the evolving field of “personalized medicine,” a move to improve health care through diagnostic tests that help determine which treatments will work more effectively for each patient.
The test costs $249. Pharmacogenomics refers to a combination of pharmacology and genomics. In October, TCB reported that OneOme raised $5.25 million in new financing through a combination of equity and debt.
OneOme was founded in 2013 and has backing from Minneapolis-based Invenshure LLC, an incubator and venture investor, and Rochester-based Mayo Clinic. The technology underpinning OneOme’s software is licensed from the Mayo Clinic, which co-developed the product. OneOme started selling its product in July 2016; in December, TCB reported that the company had landed its first non-Mayo Clinic customers.
On Tuesday, the company announced that the U.S. Patent and Trademark Office issued “patent-pending” status for the RightMed test and RightMed Advisor, an online tool allowing providers to interpret test results.
“Obtaining the patent-pending status for the OneOme platform is significant. It provides proof of our proprietary knowledge and underscores the unique solution OneOme provides, via a sophisticated and complex algorithm, to determine appropriate prescription drugs based on individual patients’ DNA,” said Paul Owen, CEO of OneOme, in a statement. “Ultimately, our goal is to help physicians and their patients as they select the most effective prescription for their unique DNA in the most timely manner possible.”